Telitacicept
Pharmaceutical drug
From Wikipedia, the free encyclopedia
Telitacicept (trade name Tai'ai) is a pharmaceutical drug used for the treatment of systemic lupus erythematosus (SLE).[1] It is being developed by Yantai Rongchang Pharmaceuticals and RemeGen for various autoimmune diseases.[2] In 2021, telitacicept was approved in China for the treatment of patients with active SLE.[3] It is also being studied for the treatment of rheumatoid arthritis (RA) and multiple sclerosis (MS).[3]
| Clinical data | |
|---|---|
| Trade names | Tai'ai |
| Other names | RC18 |
| Routes of administration | Injection |
| Legal status | |
| Legal status |
|
| Identifiers | |
| CAS Number | |
| UNII | |
Telitacicept is a fusion protein that combines a recombinant transmembrane activator and calcium modulator and cyclophilin ligand interactor (TACI) and a fragment of human immunoglobulin G (IgG).[3]